(ISSN: 0973-7049(P))

The Bioscan AN INTERNATIONAL QUARTERLY JOURNAL OF LIFE SCIENCES 21(4): S.I (4),986-996, 2026 www.thebioscan.com

FINANCIAL PERFORMANCE AND GROWTH PROSPECTS OF THE INDIAN PHARMACEUTICAL INDUSTRY: A REVIEW OF PROFITABILITY, INNOVATION, AND EMERGING CHALLENGES

[1]Dr.Sharmila Begum. A, [2]Dr. U. Jothimani

1. Assistant Professor, PG & Research Centre for Commerce, Thiruvalluvar College, Papanasam, Tirunelveli -627425, Affiliated to Manonmaniam Sundaranar University, Abishekapatti, Tirunelveli-627012, Tamil Nadu, India.

Email: shreekhan@gmail.com

2. Assistant Professor, PG & Research Centre for Commerce, Thiruvalluvar College, Papanasam, Tirunelveli -627425, Affiliated to Manonmaniam Sundaranar University, Abishekapatti, Tirunelveli-627012, Tamil Nadu, India.

Email: jothimani.u@gmail.com

DOI: https://doi.org/10.63001/tbs.2026.v21.i04.S.I(4).pp986-996

KEYWORDS

Indian Pharmaceutical Industry, Financial Performance, Profitability, Pharmaceutical Exports, Research and Development, Innovation.

Article Info

Received:02.10.2026

Accepted: 28.10.2026

Published: 11.11.2026

Abstract

The Indian pharmaceutical industry is an important contributor to the country's economic development and global healthcare supply. India has established a strong position in the production and supply of generic medicines, vaccines and pharmaceutical formulations. The industry has experienced considerable growth due to increasing domestic healthcare demand, export expansion, manufacturing capabilities and government policy initiatives. However, the sector also faces challenges associated with global competition, regulatory compliance, research and development expenditure, dependence on imported raw materials and pricing pressures. The present paper reviews the financial performance and growth prospects of the Indian pharmaceutical industry, with particular emphasis on profitability, innovation, exports, investment opportunities and emerging challenges. The study is based on secondary information collected from government reports, industry publications, official websites and relevant research literature. Available industry data indicate that the annual turnover of the pharmaceutical sector increased from ₹3,28,054 crore in FY 2020–21 to ₹4,71,898 crore in FY 2024–25. The findings highlight the importance of innovation, export diversification, domestic manufacturing and operational efficiency in sustaining future growth. The paper concludes that the Indian pharmaceutical industry has significant opportunities for expansion, provided that companies strengthen research capabilities, maintain quality standards and improve financial and technological competitiveness.

1. Introduction

The pharmaceutical industry plays a significant role in public health, economic development and industrial growth. It is responsible for the

research, development, manufacturing and distribution of medicines used for the prevention, diagnosis and treatment of diseases. The industry also contributes to employment generation, international trade, scientific research and technological development.

India has emerged as one of the major pharmaceutical manufacturing centres in the world. The country is recognised for its cost-effective production of generic medicines, vaccines and pharmaceutical formulations. Indian pharmaceutical companies supply medicines to domestic and international markets and contribute to the availability of affordable healthcare products.

The Indian pharmaceutical industry is characterised by a combination of large multinational companies, domestic manufacturers, biotechnology enterprises and small and medium-scale pharmaceutical units. The sector includes several important segments, such as formulations, bulk drugs, active pharmaceutical ingredients (APIs), vaccines, biosimilars and contract research and manufacturing services.

According to the Department of Pharmaceuticals, India ranked third globally by pharmaceutical production volume and eleventh by value. The annual turnover of the sector reached ₹4,71,898 crore in FY 2024–25. The industry has also maintained a strong export presence, with pharmaceutical exports valued at ₹2,45,962 crore during the same financial year. These figures demonstrate the importance of the pharmaceutical sector in India's manufacturing and export economy (Department of Pharmaceuticals, 2025–26).

Financial performance in the pharmaceutical industry depends on several factors, including revenue growth, production efficiency, operating margins, research expenditure, regulatory compliance, product innovation and international market access. Companies must balance investment in research and development with the need to maintain profitability and financial stability.

The present review examines the financial performance and growth prospects of the Indian pharmaceutical industry by analysing available industry-level indicators and discussing the opportunities and challenges influencing its future development.

2. Overview of the Indian Pharmaceutical Industry

The Indian pharmaceutical industry has developed into a major supplier of generic medicines and vaccines. Its competitive strength is supported by manufacturing capacity, technical expertise, a skilled workforce and cost-efficient production systems.

India supplies a significant proportion of generic medicines used across international markets. Its pharmaceutical manufacturing network includes facilities producing formulations, APIs, vaccines and other healthcare products.

The industry is also supported by a wide network of research institutions, universities, contract research organisations and biotechnology companies. These organisations contribute to drug development, formulation improvement, clinical research and manufacturing innovation.

2.1 Major Segments of the Pharmaceutical Industry

The Indian pharmaceutical industry can be divided into several major segments.

Table 1. Major segments of the Indian pharmaceutical industry

Segment	Description	Economic Contribution
Formulations	Finished medicines such as tablets, capsules and injections	Domestic and export revenue
Active Pharmaceutical Ingredients	Active substances used in medicine production	Manufacturing supply chain
Generic medicines	Off-patent medicines produced at	Affordable healthcare

	competitive prices	and exports
Vaccines	Products used for disease prevention	Public health and international supply
Biosimilars	Biological products comparable to approved reference biologics	Advanced therapeutic markets
Contract research and manufacturing	Research, development and production services for other companies	Investment and service revenue

Source: Researcher's classification based on the structure of the pharmaceutical industry.

2.2 Role of Pharmaceutical Companies in Economic Development

Pharmaceutical companies contribute to economic development through manufacturing investment, employment generation, export earnings and research activities. The sector also supports related industries such as chemical manufacturing, packaging, logistics, biotechnology and healthcare services.

The development of pharmaceutical manufacturing facilities increases industrial capacity and creates opportunities for skilled professionals in chemistry, microbiology, biotechnology, pharmacy, engineering and quality assurance.

3. Growth of the Indian Pharmaceutical Industry

The pharmaceutical sector has experienced consistent expansion over recent financial years. Growth has been supported by domestic demand, export opportunities, increased healthcare awareness and improvements in manufacturing capacity.

According to the Department of Pharmaceuticals' annual report, the industry's annual turnover increased from ₹3,28,054 crore in FY 2020–21 to ₹4,71,898 crore in FY 2024–25.

Table 2. Annual turnover of the Indian pharmaceutical industry

Financial Year	Annual Turnover (₹ crore)	Annual Growth (%)
2020–21	3,28,054	13.12
2021–22	3,44,125	4.89
2022–23	3,79,450	10.27
2023–24	4,17,345	9.99
2024–25	4,71,898	13.07

Source: Department of Pharmaceuticals, Annual Report 2025–26; underlying figures attributed in the report to Pharmarack, NPPA and DGCIS.


The data indicate that the pharmaceutical industry's annual turnover increased throughout the five-year period. The highest annual growth in the presented series occurred in FY 2024–25, at 13.07%. This growth reflects the expanding scale of pharmaceutical business activities in India.

3.1 Interpretation of Industry Growth

The increase in annual turnover indicates the expansion of pharmaceutical production and sales. The growth may be associated with increased demand for medicines, expansion into international markets, improved manufacturing capacity and the development of new product categories.

However, turnover growth should not be treated as equivalent to profit growth. Changes in production costs, raw material prices, employee expenses, research expenditure and regulatory costs may influence the actual profitability of pharmaceutical companies.

Figure 1. Annual turnover of the Indian pharmaceutical industry (FY 2020–21 to FY 2024–25)



4. Financial Performance of the Pharmaceutical Industry

Financial performance refers to the ability of a company or industry to generate revenue, control costs, manage financial resources and earn profits. In the pharmaceutical sector, financial performance is influenced by manufacturing efficiency, product demand, research and development investment, market competition and regulatory requirements.

4.1 Revenue Growth

Revenue growth is an important indicator of business expansion. Pharmaceutical companies generate revenue through domestic sales, exports, licensing arrangements, contract manufacturing and other commercial activities.

Growth in domestic healthcare demand creates opportunities for companies to expand their product portfolios. Similarly, international markets provide opportunities for manufacturers to increase sales through generic formulations, APIs and specialised pharmaceutical products.

4.2 Profitability

Profitability measures the ability of a company to generate earnings from its business activities. Common indicators include:

- Gross profit margin
- Operating profit margin
- Net profit margin
- Return on assets
- Return on equity

Pharmaceutical companies may experience differences in profitability depending on their product mix, research expenditure, manufacturing costs, export exposure and business strategies.

Companies with strong product portfolios and efficient manufacturing operations may be better positioned to maintain operating margins. However, increased research expenditure and regulatory compliance costs may influence short-term profitability.

4.3 Operating Efficiency

Operating efficiency refers to the effective utilisation of production facilities, human resources, financial capital and technology. Efficient production systems can reduce manufacturing costs and improve product quality.

Automation, digital manufacturing, quality management systems and supply chain

coordination can support operational efficiency. These improvements may also strengthen the financial position of pharmaceutical companies.

5. Pharmaceutical Exports and International Competitiveness

Exports are an important component of the Indian pharmaceutical industry's financial development. Indian manufacturers supply pharmaceutical products to several international markets, including the United States, the United Kingdom, Europe, Africa, Asia and Latin America.

The Department of Pharmaceuticals reported pharmaceutical exports of ₹2,45,962 crore in FY 2024–25, compared with imports of ₹63,573 crore. This indicates the importance of pharmaceutical exports in India's international trade.

Table 3. Pharmaceutical exports and imports in India during FY 2024–25

Indicator	Value (₹ crore)
Pharmaceutical exports	2,45,962
Pharmaceutical imports	63,573
Export value minus import value	1,82,389

Source: Department of Pharmaceuticals, Annual Report 2025–26.

The difference between exports and imports indicates a positive trade balance for the pharmaceutical sector based on the reported values. It demonstrates India's role as an important supplier of pharmaceutical products to international markets.

5.1 Major Factors Supporting Export Growth

1. Competitive manufacturing costs.
2. Established generic medicine production.
3. International demand for affordable medicines.
4. Manufacturing facilities serving regulated markets.
5. Development of pharmaceutical formulations.
6. Expansion of export destinations.
7. Availability of skilled technical professionals.

5.2 Challenges in International Markets

Indian pharmaceutical companies must comply with the regulatory requirements of importing countries. Quality inspections, documentation, product approvals and manufacturing standards influence market access.

Companies exporting to highly regulated markets must maintain effective quality assurance systems and respond to regulatory observations. Changes in international trade policies, pricing competition and currency fluctuations may also affect export performance.

6. Research and Development in the Pharmaceutical Industry

Research and development is a major driver of innovation and long-term competitiveness in the pharmaceutical sector. It involves the discovery of new compounds, development of formulations, improvement of existing medicines, clinical research and evaluation of manufacturing technologies.

Indian pharmaceutical companies have traditionally developed strong capabilities in generic medicine manufacturing. However, increasing competition and changing market requirements have created a need for greater investment in innovative research.

6.1 Importance of Research and Development

Research and development contributes to:

- Development of new pharmaceutical formulations.
- Improvement of drug delivery systems.
- Development of biosimilars and biological products.
- Improvement in manufacturing processes.
- Development of complex generic medicines.

- Strengthening of product quality and safety.
- Creation of intellectual property and competitive advantages.

6.2 Research and Development and Financial Performance

R&D expenditure may increase operating costs in the short term. However, successful research programmes may create long-term commercial opportunities through new products, patents, licensing and entry into specialised markets.

The financial impact of research investment depends on the success rate of development programmes, time to market, regulatory approval and commercial acceptance.

Table 4. Relationship between research and development and financial performance

R&D Activity	Expected Strategic Benefit	Possible Financial Implication
New drug development	Innovative products	High initial investment
Generic formulation development	Market expansion	Additional revenue opportunities
Biosimilar research	Entry into biological markets	Long-term investment requirements
Process innovation	Improved production efficiency	Potential cost reduction
Drug delivery research	Improved product differentiation	Development and commercialisation costs
Clinical research	Evidence for product approval	Research and regulatory expenditure

Source: Researcher's conceptual analysis.

7. Government Initiatives Supporting Pharmaceutical Growth

Government policies play an important role in strengthening pharmaceutical manufacturing, research and exports. Several initiatives have been introduced to increase domestic production capacity and reduce dependence on imported pharmaceutical raw materials.

7.1 Production Linked Incentive Scheme

The Production Linked Incentive (PLI) schemes aim to encourage domestic manufacturing and investment in selected pharmaceutical products and medical devices. The initiatives are intended to strengthen manufacturing capabilities and improve the competitiveness of Indian companies.

According to government information, the pharmaceutical PLI initiatives have supported investment and the creation of manufacturing capacity for selected bulk drugs, intermediates and formulations.

7.2 Promotion of Domestic API Manufacturing

Active pharmaceutical ingredients are essential components of finished medicines. Domestic API manufacturing is important for strengthening supply chain security and reducing dependence on imported raw materials.

Government support for bulk drug parks and API manufacturing can contribute to the development of domestic production facilities and improve supply chain resilience.

7.3 Research and Innovation Support

Research funding, biotechnology development programmes and collaboration between industry and academic institutions can support pharmaceutical innovation. These initiatives are important for developing new products and improving technological capabilities.

Table 5. Major growth-supporting initiatives and their expected contributions

Initiative or Policy Area	Primary Focus	Expected Contribution
Pharmaceutic	Domestic	Increased

al PLI schemes	manufacturing	production capacity
Bulk drug parks	API and intermediate manufacturing	Supply chain strengthening
Biotechnology support	Advanced biological products	Innovation and technology development
Research collaboration	Industry-academic cooperation	Scientific knowledge development
Export promotion	International market access	Export diversification

Source: Researcher's summary of government policy areas. Specific scheme allocations and outcomes should be verified from the relevant official scheme documents before publication.

8. Emerging Trends in the Indian Pharmaceutical Industry

The pharmaceutical industry is undergoing technological and structural changes. Emerging technologies and new therapeutic approaches are creating opportunities for manufacturers and research organisations.

8.1 Biotechnology and Biosimilars

Biotechnology-based medicines are an important area of pharmaceutical development. Biosimilars provide opportunities for companies to participate in advanced therapeutic markets. Their development requires specialised research, manufacturing infrastructure and regulatory expertise.

8.2 Artificial Intelligence in Drug Discovery

Artificial intelligence and machine learning can support drug discovery, molecular screening, clinical trial planning and analysis of biological data. These technologies may help researchers identify promising drug candidates and improve research efficiency.

However, the application of AI in pharmaceutical research requires reliable datasets, scientific validation, data security and regulatory oversight.

8.3 Digital Manufacturing

Digital technologies can support production monitoring, quality control, inventory management and supply chain coordination. Automation and data-based decision-making may improve manufacturing efficiency.

8.4 Contract Research and Manufacturing

Contract research, development and manufacturing services provide opportunities for Indian companies to support international pharmaceutical businesses. This segment can generate service revenue and strengthen the country's role in global pharmaceutical supply chains.

9. Major Challenges Affecting Financial Performance

Despite its growth opportunities, the Indian pharmaceutical industry faces several challenges that may influence profitability and financial stability.

9.1 Regulatory Compliance

Pharmaceutical manufacturing is subject to strict quality and safety regulations. Companies must maintain appropriate manufacturing practices, documentation, validation and quality control systems. Compliance requires continuous investment in infrastructure and skilled personnel.

9.2 Raw Material Dependency

Dependence on imported APIs, intermediates and other raw materials can expose manufacturers to international supply disruptions, price fluctuations and currency movements.

9.3 Research and Development Costs

The development of innovative medicines requires considerable financial resources. Research programmes may involve lengthy development periods and uncertain outcomes. These factors can affect the financial planning of pharmaceutical companies.

9.4 Price Competition

Generic pharmaceutical markets are highly competitive. Price reductions may increase market access but can also place pressure on operating margins.

9.5 Intellectual Property and Patent Issues

Intellectual property protection is important for innovation and commercial competitiveness. Pharmaceutical companies must manage patent-related risks while complying with applicable laws and regulatory requirements.

9.6 Global Market Uncertainty

Changes in international trade policies, exchange rates, geopolitical conditions and regulatory requirements may influence export performance and profitability.

Table 6. Major challenges and possible strategic responses

Challenge	Potential Financial Impact	Suggested Response
Regulatory compliance	Increased operating expenditure	Strengthen quality systems
Imported raw materials	Procurement cost fluctuations	Diversify suppliers
High R&D expenditure	Pressure on short-term profitability	Improve research prioritisation
Price competition	Reduced operating margins	Product differentiation
Patent-related risks	Legal and commercial uncertainty	Strengthen intellectual property management
Global market uncertainty	Export revenue fluctuations	Diversify export markets

10. Growth Opportunities and Future Prospects

The Indian pharmaceutical industry has considerable opportunities for future expansion. Increasing healthcare demand, population growth, chronic disease management, biotechnology development and international demand for affordable medicines are important growth drivers.

10.1 Expansion of Domestic Healthcare Demand

The increasing demand for medicines creates opportunities for pharmaceutical manufacturers. Growth in chronic disease management, preventive healthcare and improved access to medical services may support the expansion of pharmaceutical sales.

10.2 Export Diversification

Companies can reduce dependence on individual markets by expanding into additional geographical regions. Diversification may improve export resilience and create new revenue opportunities.

10.3 Development of Complex Generics

Complex generics require specialised formulation and manufacturing capabilities. Companies that successfully develop these products may strengthen their competitive position in selected international markets.

10.4 Biotechnology and Specialised Medicines

Biological products, biosimilars and specialised therapies represent important areas for long-term investment. These areas require research expertise, advanced manufacturing and regulatory capabilities.

10.5 Collaboration Between Industry and Academic Institutions

Universities and research institutions can contribute to drug discovery, analytical research, biotechnology and pharmaceutical product development. Stronger collaboration may support innovation and the development of skilled human resources.

11. SWOT Analysis of the Indian Pharmaceutical Industry

SWOT analysis provides an overview of the industry's internal strengths and weaknesses and its external opportunities and threats.

Table 7. SWOT analysis of the Indian pharmaceutical industry

Strengths	Weaknesses
Strong generic medicine manufacturing base	Dependence on imported inputs in some segments

Established export network	Uneven R&D capabilities across companies
Cost-efficient manufacturing	Exposure to price competition
Skilled pharmaceutical workforce	High compliance and quality investment requirements
Opportunities	**Threats**
Growth in biotechnology and biosimilars	International regulatory challenges
Expansion into emerging markets	Global pricing pressure
Development of complex generics	Supply chain disruptions
AI-supported pharmaceutical research	Currency and trade policy uncertainty

Source: Researcher's analytical assessment based on the reviewed industry information.

12. Findings of the Study

The review of available industry information provides the following observations:

1. India has established a significant position in global pharmaceutical manufacturing and generic medicine supply.
2. The industry's annual turnover increased from ₹3,28,054 crore in FY 2020–21 to ₹4,71,898 crore in FY 2024–25.
3. The reported annual turnover growth reached 13.07% in FY 2024–25.
4. Pharmaceutical exports reached ₹2,45,962 crore in FY 2024–25.
5. The reported value of pharmaceutical exports was considerably higher than imports during the same financial year.
6. Research and development is important for long-term competitiveness and product innovation.
7. Biotechnology, biosimilars, complex generics and digital manufacturing offer opportunities for future growth.
8. Regulatory compliance, raw material dependency and price competition remain important challenges.
9. Government manufacturing initiatives may support domestic production and supply chain resilience.
10. Export diversification and research collaboration can strengthen the industry's long-term growth prospects.

13. Suggestions

1. Pharmaceutical companies should increase investment in research and development according to their financial capacity and strategic priorities.
2. Domestic API manufacturing should be strengthened to improve supply chain resilience.
3. Companies should adopt advanced manufacturing and quality control technologies.
4. Export markets should be diversified to reduce excessive dependence on a limited number of destinations.
5. Collaboration between universities, research institutions and pharmaceutical industries should be encouraged.
6. Companies should strengthen regulatory compliance and quality assurance systems.
7. AI and digital technologies should be adopted where they provide measurable improvements in research and manufacturing.

8. Small and medium pharmaceutical manufacturers should receive appropriate technical and infrastructure support.
9. Financial management practices should focus on balancing profitability, innovation expenditure and long-term investment.
10. Companies should develop strategies for biotechnology, biosimilars and complex generic products.

14. Conclusion

The Indian pharmaceutical industry has emerged as an important contributor to national economic development and global healthcare supply. Its growth is supported by generic medicine manufacturing, export expansion, domestic healthcare demand and increasing production capacity. The increase in annual industry turnover from ₹3,28,054 crore in FY 2020–21 to ₹4,71,898 crore in FY 2024–25 demonstrates the expansion of the sector during the period reviewed.

However, future growth will depend not only on revenue expansion but also on profitability, innovation, manufacturing efficiency and international competitiveness. Pharmaceutical companies must address challenges related to regulatory compliance, raw material dependency, research expenditure and global pricing pressures.

Greater investment in research and development, biotechnology, complex generics, domestic API production and digital manufacturing can create opportunities for sustainable growth. Stronger collaboration between industry, academia and government institutions may further improve India's pharmaceutical research and manufacturing capabilities.

The study concludes that the Indian pharmaceutical industry has promising growth prospects. A balanced approach combining financial discipline, technological innovation, quality assurance and export diversification will be important for maintaining its competitive position in the global pharmaceutical market.

References

1. Department of Pharmaceuticals. (2025–26). *Annual Report 2025–26*. Ministry of Chemicals and Fertilizers, Government of India. https://pharma-dept.gov.in/sites/default/files/Annual%20Report%202025-26_0.pdf
2. Department of Pharmaceuticals. (n.d.). *Annual Reports*. Government of India. https://www.pharma-dept.gov.in/en/annual-report
3. Press Information Bureau. (2025). *India's Pharma Edge: Scaling Manufacturing and Exports*. Government of India. https://www.pib.gov.in/FactsheetDetails.aspx?Id=150923&lang=3&reg=3
4. India Brand Equity Foundation. (2026). *Indian Pharmaceuticals Industry Analysis*. https://www.ibef.org/industry/indian-pharmaceuticals-industry-analysis-presentation
5. India Brand Equity Foundation. (n.d.). *Indian Pharmaceutical Industry*. https://www.ibef.org/industry/pharmaceutical-india
6. NITI Aayog. (2026). *Mapping the Global Trade Profile in Pharmaceutical Products*. Government of India. https://www.niti.gov.in/node/2342
7. Ministry of Commerce and Industry. (2024). *Annual Report 2023–24*. Government of India. https://www.commerce.gov.in/wp-content/uploads/2024/12/Annual-Report-English-Lower-Resolution-1.pdf
8. Tofler. (2025). *India Pharma Industry Benchmarking Report: FY 2020–21 to FY 2024–25*. https://www.tofler.in/industry-reports/pharma

9. Sultana. (2017). Impact of financial ratios on profitability—An analysis of select pharmaceutical companies in India. *International Journal of Management and Development Studies, 6*(11), 11–22. https://doi.org/10.53983/ijmds.v6i11.335

10. Yameen, M., Farhan, N. H. S., & Tabash, M. I. (2019). The impact of liquidity on firms' performance: Empirical investigation from Indian pharmaceutical companies. *Academic Journal of Interdisciplinary Studies, 8*(3), 212. https://doi.org/10.36941/ajis-2019-0019